Press Releases

You will find all our regulatory press releases in the feed below. Enjoy and share all our other Asarina Pharma news in our regularly updated News Archive.

   

First patient dosed in landmark Menstrual Migraine study

Asarina Pharma AB (publ) (ASAP: FN Stockholm) has administered the first dose in its Phase IIa trial of a new, preventative treatment for menstrual migraine. Sepranolone is the first woman-only migraine treatment, specifically targeting menstrual migraine.

Full PDF
   

Asarina Pharma AB (publ) Interim Report Q3 2019 released

Asarina Pharma CEO Peter Nordkild: “During an intense third quarter we achieved some important milestones. We enrolled the last patient in our landmark PMDD study, received FDA approval for our IND in menstrual migraine and included the first patient in our menstrual migraine study. After the end of the quarter a new directed share issue…

Full PDF
Asarina-Pharma Q3-2019 master2
   

Asarina Pharma has completed a directed share issue of approximately SEK 48 million

Asarina Pharma AB (publ) (Nasdaq First North Growth Market: ASAP) (”Asarina Pharma” or the “Company”) today announces that the Company has successfully completed a directed share issue of 2,159,148 shares, corresponding to approximately SEK 48 million. In addition, existing shareholders have due to high demand sold 764,329 existing shares, corresponding to approximately SEK 17 million,…

Full PDF
   

Asarina Pharma intends to carry out a directed share issue

Asarina Pharma AB (publ) (Nasdaq First North Growth Market: ASAP) (”Asarina Pharma” or the “Company”) today announces its intention to execute a directed share issue to institutional investors (the “Issue”).

Full PDF
   

First patient included in menstrual migraine study

Asarina Pharma AB (publ) (ASAP: FN Stockholm) today announced the first patient has been included in its Phase IIa trial of Sepranolone in menstrual migraine (MM). The study will include 80-90 patients and is expected to be completed by the end of 2020.

Full PDF